Peptris Technologies Private

Executive Summary

Peptris Technologies Private is an AI-powered preclinical drug discovery company based in Bangalore, India, founded in 2020. The company leverages proprietary machine learning and generative AI to design novel chemical entities, repurpose approved drugs, and rescue clinical candidates. Its platform integrates unsupervised learning and large language models to generate optimized molecules with enhanced activity and drug-like properties. Peptris focuses on oncology, inflammation, and rare diseases, operating virtually by outsourcing wet lab work to CROs. With $8.4 million in total funding, the company aims to accelerate the discovery of high-quality preclinical candidates for unmet medical needs. Peptris is positioned to capitalize on the growing adoption of AI in drug discovery, targeting a platform stage with potential for multiple programs. The company's virtual model allows efficient capital deployment, and its focus on diverse therapeutic areas broadens partnership opportunities. Upcoming catalysts include lead optimization milestones, strategic collaborations with pharmaceutical companies, and a potential Series A funding round to support pipeline advancement. While early-stage, Peptris' technology and focus on validated targets provide a solid foundation for value creation.

Upcoming Catalysts (preview)

• Q4 2026Lead optimization program for oncology candidate60% success
• Q1 2027Strategic partnership with pharma for inflammation program40% success
• Q3 2026Series A funding round70% success